Kevin R. Kaster
Directeur/Bestuurslid bij Cure DM, Inc.
Profiel
Kevin R.
Kaster was the founder of Alvine Pharmaceuticals, Inc. founded in 2005, where he held the title of Vice President-Corporate Development.
He currently holds positions at Cure DM, Inc. as Director and at Lyric Pharmaceuticals, Inc. as Vice President-Intellectual Property.
Mr. Kaster's former positions include Research Scientist at Eli Lilly & Co., Vice President-Intellectual Property at Kosan Biosciences, Inc. from 1998 to 2002, Vice President-Development at Threshold Pharmaceuticals, Inc. from 2002 to 2007, and Vice President-Patents & Licensing at Eiger BioPharmaceuticals, Inc. Mr. Kaster received his undergraduate degree from Vanderbilt University and his graduate degree from Indiana University Maurer School of Law.
Actieve functies van Kevin R. Kaster
| Bedrijven | Functie | Begin |
|---|---|---|
Lyric Pharmaceuticals, Inc.
 Lyric Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lyric Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. The firm develops novel gastrointestinal therapeutics for unmet medical needs in the hospital settings. The company was founded by David Wurtman and M. Scott Harris in 2013 and is headquartered in South San Fancisco, CA. | Corporate Officer/Principal | - |
Cure DM, Inc.
 Cure DM, Inc. BiotechnologyHealth Technology Cure DM, Inc. operates as a biopharmaceutical company. It develops new therapies that may prevent, ameliorate or reverse diabetes and allow for the discontinuation of insulin. The company was founded by Loraine V. Upham, Claresa S. Levetan and Rita El-Hajj in 2004 and is headquartered in Wilmington, DE. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Kevin R. Kaster
| Bedrijven | Functie | Einde |
|---|---|---|
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Corporate Officer/Principal | 02-11-2002 |
Kosan Biosciences, Inc.
 Kosan Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Kosan Biosciences, Inc. develops drugs for cancer therapeutics. The company was founded in 1995 and is headquartered in New York, NY. | Corporate Officer/Principal | 01-01-2002 |
Eiger BioPharmaceuticals, Inc. /Old/
 Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | Corporate Officer/Principal | - |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Alvine Pharmaceuticals, Inc.
 Alvine Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Alvine Pharmaceuticals, Inc. develops and commercializes therapeutics for inflammatory diseases. It offers ALV003, tTG Inihibitors and HLA-DQ2 Blockers. The company was founded by Blair Stewart and Kevin R. Kaster in 2005 and is headquartered in San Carlos, CA. | Oprichter | - |
Opleiding van Kevin R. Kaster
| Vanderbilt University | Undergraduate Degree |
| Indiana University Maurer School of Law | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| Bedrijven in privébezit | 6 |
|---|---|
Alvine Pharmaceuticals, Inc.
Alvine Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Alvine Pharmaceuticals, Inc. develops and commercializes therapeutics for inflammatory diseases. It offers ALV003, tTG Inihibitors and HLA-DQ2 Blockers. The company was founded by Blair Stewart and Kevin R. Kaster in 2005 and is headquartered in San Carlos, CA. | Health Technology |
Kosan Biosciences, Inc.
Kosan Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Kosan Biosciences, Inc. develops drugs for cancer therapeutics. The company was founded in 1995 and is headquartered in New York, NY. | Health Technology |
Eiger BioPharmaceuticals, Inc. /Old/
Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | Health Technology |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
Lyric Pharmaceuticals, Inc.
Lyric Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lyric Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. The firm develops novel gastrointestinal therapeutics for unmet medical needs in the hospital settings. The company was founded by David Wurtman and M. Scott Harris in 2013 and is headquartered in South San Fancisco, CA. | Health Technology |
Cure DM, Inc.
Cure DM, Inc. BiotechnologyHealth Technology Cure DM, Inc. operates as a biopharmaceutical company. It develops new therapies that may prevent, ameliorate or reverse diabetes and allow for the discontinuation of insulin. The company was founded by Loraine V. Upham, Claresa S. Levetan and Rita El-Hajj in 2004 and is headquartered in Wilmington, DE. | Health Technology |
